FDA Grants Priority Review for Pfizer's Marstacimab (BLA761369)
The FDA has granted priority review status for Pfizer's BLA761369, containing the active ingredient Marstacimab.
Asset / Drug
Drug and asset intelligence for Marstacimab with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
Monoclonal Antibody
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.